Investment
New lead investor in Xeltis's additional €20.5M funding tranche to advance the aXess vascular access conduit toward FDA approval and US commercial launch.
Xeltis
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Xeltis
Neuren Pharmaceuticals
Volpara Health